1	Fluorescent Antibody-Based Detection and Ultrastructural Analysis of Streptococcus
2	pneumoniae in Human Sputum
3	
4	Ana G. Jop Vidal ^{1,#} , Meg Francis ^{1,#} , Maneesha Chitanvis ⁴ , Ithiel J. Frame ^{3,*} , Poonam Sharma ³ ,
5	Patricio Vidal ¹ , Claudio F. Lanata ⁵ , Carlos Grijalva ⁶ , William Daley ³ , and Jorge E. Vidal ^{1,2}
6	
7	¹ Department of Cell and Molecular Biology, ² Center for Immunology and Microbial Research,
8	³ Department of Pathology, University of Mississippi Medical Center, Jackson MS; ⁴ Rollins School
9	of Public Health; Emory University, Atlanta GA; ⁵ Instituto de Investigacion Nutricional; Lima,
10	Peru; ⁶ Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN
11	
12	[#] These authors contributed equally to the manuscript
13	*Current affiliation: Quest Diagnostics, Lewisville, TX
14	
15	Running title: Spn-FLUO for pneumococcal detection in sputum
16	
17	Address correspondence to:
18	Jorge E. Vidal, PhD. Department of Cell and Molecular Biology, University of Mississippi Medical
19	Center. 2500 North State St, Jackson MS 39216. Email: jvidal@umc.edu
20	
21	

2-Oct-24

22 Abstract

23 Background: Pneumococcal pneumonia continues to be a significant global health burden, 24 affecting both children and adults. Traditional diagnostic methods for sputum analysis remain 25 challenging. The objective of this study was twofold: to develop a rapid and easy-to-perform 26 assay for the identification of *Streptococcus pneumoniae* (Spn) directly in sputum specimens using fluorescence microscopy, and to characterize with high-resolution confocal microscopy 27 28 the ultrastructure of pneumococci residing in human sputum. *Methods:* We fluorescently 29 labeled antibodies against the pneumococcal capsule (Spn-FLUO). The specificity and sensitivity of Spn-FLUO for detecting Spn was evaluated in vitro and in vivo using mouse models of 30 31 carriage and disease, human nasopharyngeal specimens, and sputum from patients with pneumococcal pneumonia. Spn was confirmed in the specimens using culture and a species-32 specific gPCR assays. Confocal microscopy and Imaris software analysis were utilized to resolve 33 34 the ultrastructure of pneumococci in human sputum. Results: Compared with cultures and qPCR, Spn-FLUO demonstrated high sensitivity (78-96%) in nasopharyngeal samples from mice 35 and humans. The limit of detection (LOD) in nasopharyngeal samples was $\geq 1.6 \times 10^4$ GenEq/ml. 36 37 The specificity in human nasopharyngeal specimens was 100%. In lung specimens from mice infected with pneumococci, Spn-FLUO reached 100% sensitivity with a LOD of \geq 1.39x10⁴ 38 GenEq/ml. In human sputum, the sensitivity for detecting Spn was 92.7% with a LOD of 3.6x10³ 39 40 GenEq/ml. Ultrastructural studies revealed that pneumococci are expectorated as large aggregates with a median size of 1336 μ m². *Conclusions:* Spn-FLUO is a rapid and sensitive 41 assay for detecting Spn in human sputum within 30 min. The study highlights that most 42 pneumococci form aggregates in human sputum. 43

2-Oct-24

2-Oct-24

45 Background

Streptococcus pneumoniae (Spn) strains infect the lungs causing pneumococcal 46 pneumonia, a common community-acquired pneumonia (CAP) that causes over a million 47 deaths annually worldwide¹. Pneumococcal pneumonia is an acute bacterial infection of the 48 pulmonary parenchyma caused by colonization of the lung and subsequent, or concurrent, 49 invasion of pneumococci into the respiratory epithelium^{2, 3}. Invasion of bronchi and terminal 50 bronchiole leads pneumococci to reach respiratory bronchiole, alveolar ducts, and alveoli, 51 where pneumococci have access to the alveolar-capillary network, a large surface area 52 containing \sim 300 billion of blood capillaries and where the exchange of CO₂ by O₂ occurs. 53

54 Spn strains encompass over 100 capsular types; the capsule is a target of pneumococcal 55 vaccines that have saved millions since their licensure⁴. The capsular polysaccharide is 56 negatively charged, enabling pneumococci to colonize the lungs by evading entrapment by 57 mucus secreted in the lumen of bronchi and terminal bronchiole². The capsule also acts as an 58 anti-phagocytic factor by blocking complement deposition^{2, 5, 6, 7}. Consequently, expression of 59 the pneumococcal capsule is maximized during pneumococcal pneumonia and it was utilized in 60 this study to identify the presence of Spn in clinical specimens.

The diagnosis of pneumococcal pneumonia is based on symptoms and suggestive radiographic findings^{8, 9}. Diagnostic testing to determine pneumococcal pneumonia is optional for non-hospitalized patients, while those requiring admission should undergo blood cultures, respiratory cultures, and Gram staining of good-quality sputum. If the disease is severe, a urinary antigen test may also be considered⁸. However, cultures have poor sensitivity and can

2-Oct-24

take at least 24 h to yield results. Moreover, the urinary antigen test for identifying
 pneumococcal pneumonia has limited sensitivity and specificity⁸.

Pneumonia multiplex (m)PCR panels have demonstrated superior performance in 68 detecting respiratory pathogens, including pneumococcal strains. mPCR panels offer improved 69 specificity and turnaround time compared to traditional methods¹⁰. Other molecular assays 70 71 include real-time PCR methods targeting a number of species-specific genes, or gene sequences, such as the gene encoding the autolysin $lytA^{11, 12}$, the pneumolysin p/y^{12} gene, the 72 permease gene piab of the iron transporter PiaABC¹³ or a putative transcriptional regulator 73 SP2020¹⁴. These PCR assays typically exhibit high sensitivity and specificity (>90%), and 74 depending on the platform, real-time assays can deliver results within 3-4 h. 75

Prompt and accurate identification of pneumococcal pneumonia as the etiology is 76 77 crucial for tailoring antibiotic management to a specific patient, which is paramount to preventing complications and mortality^{8, 15}. Early administration of antibiotic therapy has been 78 79 demonstrated to improve short-term mortality rates in both human patients and animal models of pneumococcal disease^{16, 17}. Antibiotic therapy for community-acquired pneumonia 80 (CAP) is typically initiated empirically within 1-2 h of presentation to a healthcare facility, prior 81 to the identification of the causative pathogen¹⁶. However, the indiscriminate use of empirically 82 prescribed antibiotics has contributed to a significant increase in antimicrobial resistance rates, 83 particularly in certain geographical regions. For example, in some areas, over 70% of Spn strains 84 isolated from pneumococcal pneumonia cases are resistant to first-line macrolide antibiotics^{18,} 85 19. 86

2-Oct-24

Addressing the global burden of antibiotic resistance requires multifaceted efforts, 87 88 including ensuring equitable access to, and developing innovative, diagnostics. In this study, we fluorescently labeled antibodies against the pneumococcal capsule, hereafter referred to as 89 Spn-FLUO, and evaluated their performance in detecting pneumococcal strains within 30 min. 90 Given the capsule's high expression during pneumococcal disease, we hypothesized that 91 92 antibodies targeting the capsule would enhance the rapid detection of strains in lower airway specimens. We systematically tested Spn-FLUO to detect Spn strains grown in vitro, as well as 93 strains colonizing the upper and lower airways of mice in murine models of carriage and 94 disease. Additionally, we assessed the efficacy of Spn-FLUO in detecting Spn strains colonizing 95 the nasopharynx of children. We evaluated the diagnostic performance of Spn-FLUO in 96 identifying pneumococcal pneumonia as the etiology in specimens collected from patients with 97 98 pneumococcal pneumonia. Results were obtained within 30 min of sample collection.

99 Given the distinctive characteristics of the pneumococci observed in the sputum, we 100 conducted additional ultrastructural studies using high-resolution laser scanning confocal 101 microscopy and advanced image analysis. Consequently, we present novel insights into the 102 ultrastructure of pneumococcal aggregates formed in human sputum.

103

104 Methods

Bacterial strains, culture media, and antibiotics. Spn reference strains and mutants used in the present study were: $TIGR4^{20}$, $SPJV41^{21, 22}$, $D39^{23}$, $EF3030^{24}$, $S19F4924^{25}$ and $S6B8655^{26}$. Strains were routinely cultured on blood agar plates (BAP), or grown in Todd Hewitt broth containing 0.5% (w/v) yeast extract (THY), at 37°C with a 5% CO₂ atmosphere. Where indicated,

2-Oct-24

streptomycin (Str, 200 μg/ml), trimethoprim (Tmp, 10 μg/ml), tetracycline (Tet, 1 μg/ml),
or/and erythromycin (Ery, 1 μg/ml) was added to BAP. All antibiotics were purchased from
Millipore-Sigma Sigma-Aldrich.

Preparation of inocula. The inoculum was prepared as previously described²⁷. Briefly, bacteria were inoculated on blood agar plates (BAP) and incubated overnight at 37°C in a 5% CO₂ atmosphere. Bacteria were then harvested from plates by PBS washes and this suspension was used to inoculate THY or cell cultures, that was brought to a final OD_{600} of ~0.1. This suspension contained ~5.15x10⁸ cfu/ml as verified by serial dilution and platting of aliquots of the suspension.

118 **Cell cultures.** Human pharyngeal Detroit 562 cells (ATCC CCL-138) were cultured in Eagle's 119 minimum essential medium (MEM) (Gibco) supplemented with non-heat-inactivated 10% fetal 120 bovine serum (FBS) from R&D systems, 1% nonessential amino acids (Gibco), 1% glutamine 121 (Gibco), penicillin (100 U/ml), and streptomycin (100 μ g/ml), and the pH was buffered with 122 HEPES (10 mM) (Gibco). Cells were harvested with 0.25% trypsin (Gibco), resuspended in the 123 cell culture medium, and incubated at 37°C in a 5% CO₂ humidified atmosphere.

Fluorescent labeling of anti-capsule antibodies. Antibodies were purchased from the Staten Serum Institute (Denmark). The following antibodies were used throughout this study: Omni antiserum (recognizes 92 serotypes), type serum 2, type serum 4, group serum 6, and group serum 19. Serum was depleted of proteins less than 100 kDa using an Amicon Ultra-100K centrifugal filter (Millipore-Sigma), washed three times with PBS. Proteins were quantified using Bradford reagent, and 1 mg of the antibodies was labeled with either Alexa-488 or Alexa-555 following the manufacturer's recommendations (Molecular Probes). After purification by size

2-Oct-24

exclusion chromatography (≥40 kDa), collected fractions were assessed for reactivity against the specific serotype, serogroup, or several serotypes for the Omni antiserum. Proteins were quantified from reactive fractions using the Bradford assay, and antisera were stored at 4°C for short-term or -20°C for long-term storage. Labeled antibodies stored at 4°C remained reactive for up to three months, while those frozen have been effective in labeling bacteria for over three years. For the sake of simplicity, the fluorescently labeled Omni antiserum is referred to

137 as Spn-FLUO throughout this manuscript.

138 In vitro imaging of pneumococci. Pneumococci were inoculated into 8-well glass slides (Lab-Tek) and incubated for 4 h at 37° C in a 5% CO₂ atmosphere. Some slides contained cultures of 139 Detroit 562 cells (ATCC CCL-198) grown to confluence, typically 7 days post seeding. 140 141 Pneumococci attached to the glass substratum or human cells were then washed twice with PBS and fixed with 2% PFA for 15 min at room temperature. After removing the 2% PFA, the 142 bacteria were washed with PBS and blocked with 2% bovine serum albumin (BSA) for 1 h at 143 144 37°C. The pneumococci were then incubated with the specified labeled antibodies (~20 μ g/ml) 145 for 1 h at room temperature. The stained preparations were subsequently washed twice with PBS and mounted with ProLong Diamond Antifade Mountant with DAPI (Molecular Probes). In 146 147 some preparations, DAPI was replaced with TO-PRO-3 (1 µM), a carbocyanine monomer nucleic acid stain (Molecular Probes). Fluorescence images were acquired using an upright, epi-148 fluorescence Nikon Ni-U Research Microscope equipped with a Nikon DS-Qi2 sCMOS Camera 149 150 system. Confocal images were obtained using a Nikon C2 laser scanning confocal microscopy 151 system, and the micrographs were analyzed with ImageJ version 1.49k (National Institutes of Health, USA) or Imaris software (Bitplane). 152

2-Oct-24

153 Mouse models of pneumococcal nasopharyngeal carriage and disease. Inbred 6-7 week-old 154 C57BL/6 mice -pneumococcal carriage-, or 4-5 week-old Balb/c mice -pneumococcal pneumonia- model (Charles River Laboratories) were anesthetized with 5% isoflurane (vol/vol) 155 156 in oxygen (2 liters/min) administered via an RC2 calibrated vaporizer (VetEquip Inc) and then infected with $\sim 1 \times 10^5$ CFU of strain Spn EF3030 (carriage model) or $\sim 1 \times 10^8$ cfu of TIGR4 or 157 158 SPJV41 (pneumonia model). The animals were weighed daily, and their behavior and appearance were monitored twice daily for up to four days. Mice in the pneumonia model were 159 160 euthanized when they lost ≥20% of their body weight, compared to their body weight before infection, or when mice were non-responsive to manual stimulation, and/or if they show signs 161 of illness such as ruffled fur, intermittent hunching, and exhibiting respiratory distress. Mice 162 163 were then euthanized, and the upper airways, including nasopharyngeal tissue or the lungs, were aseptically collected, placed in THY with 10% glycerol and immediately homogenized. For 164 fluorescence staining (explained below), the nasopharynx from some mice was collected and 165 166 fixed with 10% PFA. The specimens were then stored at -80°C. This aliquot was used for bacterial counts and detection with labeled antibodies. To obtain bacterial counts, the 167 homogenized tissue was serially diluted in PBS and plated onto BAP with gentamicin. The 168 Institutional Animal Care and Use Committee (IACUC) at the University of Mississippi Medical 169 170 Center approved the protocol used in this study (1584), overseeing the welfare, well-being, and 171 proper care of all mice utilized in this study. All mouse experiments followed the guidelines 172 outlined in the National Science Foundation Animal Welfare Act (AWA).

173 **Fluorescence staining of nasopharyngeal tissue.** The PFA-fixed nasopharynxes were paraffin-174 embedded, sectioned (~5 μ m), mounted on a slide and deparaffinized. Tissues were washed

2-Oct-24

three times with PBS and the preparations were blocked with 2% bovine serum albumin (BSA) for 1 h at room temperature. These preparations were then incubated for 1 h with serogroupspecific (S19) polyclonal antibody (Statens Serum Institute, Denmark) (20 μg/ml) that had been previously labeled with Alexa-555 (Molecular Probes). Stained tissues were finally washed three times with PBS, air dried and then mounted with ProLong Diamond Antifade mounting medium containing DAPI (Molecular Probes). Confocal micrographs were obtained using a Nikon C2 laser scanning confocal microscopy system and analyzed using the Imaris software (Bitplane).

Specimens from Humans with Pneumococcal Pneumonia. Human specimens, including 182 sputum and bronchoalveolar lavages from de-identified patients with microbiologically and 183 radiologically confirmed pneumococcal pneumonia, were utilized in this study. Institutional 184 Review Board (IRB) exemption was obtained for the use of these de-identified specimens. 185 186 When available, the age of the patients ranged from 19 months through 60 years. The specimens were collected according to institutional guidelines by the University of Mississippi 187 Medical Center's clinical laboratory and stored at -80°C until processed. As part of the 188 microbiological diagnostics, the pathology laboratory at UMMC isolated a Spn strain from each 189 specimen. Additionally, the Spn etiology was confirmed by lytA-based real-time PCR, as 190 detailed^{28, 29} and briefly described below. 191

Human nasopharyngeal specimens. Human nasopharyngeal specimens (N=50) utilized in the current study had been collected from Peruvian children and processed for pneumococcal detection and quantification by qPCR and culture in previous studies^{30, 31}. Children enrolled in the mentioned studies were aged 0-3 years of age; details on the study population have been published elsewhere^{31, 32, 33}. De-identified specimens were processed at Emory University,

2-Oct-24

obtaining IRB exemption. Briefly, these nasopharyngeal samples were collected following WHO
 recommendations³⁴ with a deep NP swab, using rayon polyester swabs and were immediately
 placed in 2.0 ml cryogenic vials with 1 ml of transport medium, a mixture containing skim milk tryptone-glucose-glycerin (STGG) and then stored at -80°C³⁵.

Identification of pneumococcus using Spn-FLUO in mouse tissue or human specimens. 201 Specimens were thawed on ice and an aliquot (10 µl) of each specimen was immediately mixed 202 203 with Spn-FLUO (50 µg/ml) and incubated for 10 min at room temperature in the dark. Five µl of this suspension was dropped onto a microscope slide and covered with a coverslip. The stained 204 sample was analyzed within five minutes using an upright, epi-fluorescence Nikon Ni-U 205 206 Research Microscope equipped with a Nikon DS-Qi2 sCMOS Camera system. We first situated the specimen in the correct optical plane (i.e., visualizing cells, tissue, and/or bacteria) with the 207 208 60x objective and a bright light source. The slides were then analyzed and scored using epifluorescence in the green channel, following a semiguantitative algorithm: 1-5 pneumococci 209 210 per field in at least three fields corresponded to "+", 5-10 pneumococci per field to "++", and more than 10 pneumococci per field was scored as "+++". Negative samples had no 211 212 pneumococci observed. Micrographs from positive specimens were obtained using the 60x and 100x objectives. 213

Staining and confocal analysis of human sputum. An aliquot of sputum sample (10 μ l) was dropped onto a slide and air dry for ~20 min at room temperature. The sputum was then stained for 1 h with Spn-FLUO (20 μ g/ml) and wheat germ agglutinin conjugated to Alexa-555 [(WGA), 5 μ g/ml]. The stained specimen was washed three times with PBS, air-dried, and mounted with ProLong Diamond Antifade mounting medium containing DAPI (Molecular

2-Oct-24

Probes). Confocal micrographs were obtained using a Nikon C2 laser scanning confocal microscopy system and z-stacks micrographs were analyzed using the NIS Elements Basic Research software, version 4.30.01 build 1021. For 3D visualization, creation of animations, and quantification purposes, images were processed using the Imaris software 64x Version 10.1.0 (Oxford Instruments).

DNA extraction and guantitative PCR (gPCR). DNA was extracted as described earlier using a 224 QIAamp DNA mini kit (Qiagen)^{30, 36}. Bacterial density was guantified by gPCR reactions in a total 225 226 25 µl volume. Reactions contained 1x Platinum qPCR superMix (Invitrogen), 200 nm each of primers and probe, and 2.5 µl of purified DNA. The nucleotide sequence of primers and probe 227 were published elsewhere¹². No template controls (NTC) were run with each set of samples. 228 qPCR reactions were carried out using a CFX96 Real-Time PCR Detection System (Bio-Rad). The 229 230 following amplification parameters were utilized, 95°C for 2 min, followed by 40 cycles of 95°C 231 for 15 s and 60°C for 1 min. qPCR standards using genomic DNA from reference strain TIGR4 (ATCC BAA-334) were run in parallel to construct a standard curve utilized to calculate genome 232 equivalents (GenEq)/ml using the software Bio-Rad CFX manager. Standards DNA Preparation: 233 234 Purified DNA was adjusted to a concentration of 1 ng/μ l in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and immediately stored at -80°C until use. Standards for quantification were 235 prepared within an hour before reactions by serially diluting a 1 ng/ μ l aliquot in TE buffer to 236 final concentrations of 100 pg/ μ l, 10 pg/ μ l, 1 pg/ μ l, 100 fg/ μ l, 50 fg/ μ l, and 5 fg/ μ l of 237 pneumococcal DNA. Given the 2.1608 Mb genome size of TIGR4²⁰, these standards 238 corresponded to 4.29×10^5 , 4.29×10^4 , 4.29×10^3 , 4.29×10^2 , 4.29×10^1 , 2.14×10^1 , or 2.14 GenEq, 239

2-Oct-24

- respectively. Standards prepared using this protocol consistently achieved an efficiency greater
 than 90% throughout the study (data not shown).
- 242

Isolation and identification of *S. pneumoniae* strains. Nasopharyngeal specimens were thawed, vortexed for 15 s and 200 μ l transferred to a 5 ml Todd-Hewitt broth (THY) containing 0.5% of yeast extract and 1 ml of rabbit serum (Gibco[®] by Life Technologies)³⁷. This enriched culture was incubated for 6 h at 37°C in a 5% CO₂ atmosphere and then inoculated onto BAP and incubated for 18-24 h at 37°C in a 5% CO₂ atmosphere. Spn strains were isolated and identified using the optochin test (Remel) and bile solubility test as previously described³⁷.

Spn strains were isolated and identified from lower respiratory tract specimens including sputum, endotracheal aspirates, bronchoalveolar lavage fluids, bronchial washings, protected brush specimens, and lung aspirates, using standard methodologies³⁸. Briefly, after Gram staining, the primary media including 5% Columbia sheep blood, Chocolate, and MacConkey agars (BD BBL[™]) were inoculated. Thioglycolate broth was employed for bronchial brush samples. The media were incubated for 18 to 24 h at 35-37°C in 5% CO₂, and cultures that remained negative after this period were re-incubated for another 24 h.

Pathogenic organisms were identified and susceptibility testing was performed only on significant growth, characterized by moderate to abundant colonies in the second or further quadrants of the plate, small numbers of a pathogen consistent with the predominant Gramstain morphotype, and associated with inflammatory white blood cells, or colonies in the first quadrant if minimal or no other normal flora was present. Alpha-hemolytic, dry, or mucoid colonies resembling Spn strains were identified using Matrix Assisted Laser Desorption

2-Oct-24

262	Ionization Time-of-Flight (VITEK [®] MS) or VITEK [®] 2 Gram-Positive identification card (GP), and
263	purity was confirmed with the optochin disc. The antibiotic sensitivity was determined using
264	VITEK [®] 2 Gram-Positive Susceptibility Cards, and the manual D-test.
265	Statistical analysis. We performed one-way analysis of variance (ANOVA) followed by Dunnett's
266	multiple-comparison test when more than two groups were compared or Student's t test to
267	compare two groups, as indicated. All statistical analysis was performed using the software
268	GraphPad Prism (version 8.3.1).

269

270 **Results**

In vitro assessment of fluorescently-labeled anti-Spn antibodies for detecting S. pneumoniae 271 strains. We first evaluated the ability of fluorescently-labeled antibodies to detect specific Spn 272 273 strains. Antibodies targeting vaccine serotypes, or serogroups, were labeled as detailed in 274 Material and Methods. In addition to their specific reactivity against corresponding 275 serotypes/serogroups, the labeled antibodies did not exhibit cross reactivity against a panel of 276 other serotypes (not shown). For instance, the anti-S4-A488 (green), or anti-S19-A555 (red) antibody specifically stained Spn serotype 4 or 19F, respectively, within five min of exposure as 277 278 evaluated by fluorescence microscopy (Fig. 1A and not shown). High-resolution micrographs using confocal microscopy were obtained from S19F strain 4924 growing on a glass substratum 279 (Fig. 1B). 280

We next evaluated the detection of Spn strains using fluorescently labeled antibodies in strains infecting *in vitro*-cultured human pharyngeal cells. Pharyngeal cells were infected for four h with strain D39 (serotype 2) or with a mixture of strains D39 and TIGR4 (serotype 4), and

2-Oct-24

subsequently stained with anti-S2-A555 or with a combination of anti-S2-A555 and anti-S4-A488. Cell nuclei were also stained with a fluorescent dye. Spn strains were identified in cells infected with a single serotype (Fig. 1C). Additionally, each individual Spn strain was detected on pharyngeal cells infected with the D39-TIGR4 mixture (Fig. 1D).

288

Detection of Spn vaccine strain serotype 19F in the mouse upper respiratory tract. A murine model of nasopharyngeal carriage was employed to assess the utility of fluorescent antibodies for detecting Spn strains. Eleven mice were intranasally inoculated with ~10⁵ colony-forming units (CFU) of Spn strain EF3030, a serotype 19F strain commonly used in animal models of pneumococcal carriage^{24, 39}. This inoculum was previously optimized to induce colonization levels comparable to those observed in the nasopharynx of children^{33, 40}.

Two days post-infection, nasopharyngeal tissue from the upper respiratory tract was 295 296 collected and stored in paraformaldehyde or homogenized. An aliquot of the nasopharyngeal 297 homogenate was subjected to serial dilution and plating to quantify the pneumococcal burden. All mice were colonized with a median bacterial load of 7.2×10^4 cfu/organ (interguartile range: 298 7.1×10^4 - 3.3×10^5) (Table 1). Subsequently, aliquots of the nasopharyngeal homogenates were 299 subjected to pneumococcal detection assays. We employed an anti S19-A555 antibody, known 300 to recognize strain serotype 19F EF3030⁴¹, and Spn-FLUO antibody raised against 92 301 302 pneumococcal serotypes, including serotype 19F. Both antibodies detected pneumococci in 72% of the specimens (8/11) (Fig. 1E and Table 1). Detection of pneumococci was not achieved 303 in nasopharyngeal homogenates with a bacterial density $\leq 7.1 \times 10^3$ cfu/organ (Fig. 1G and Table 304 1). Histological analysis of nasopharyngeal tissue revealed intracellular pneumococci within 305

2-Oct-24

306 goblet cells indicating a good performance of antibody-based detection at the tissue level (Fig.
307 1F).

308

Phenotypic and genotypic identification of *S. pneumoniae* in human nasopharyngeal specimens. For this initial proof-of-concept study, we selected fifty nasopharyngeal specimens from children from our previous studies^{28, 30, 42} and were divided into two groups (N=25 each) as detailed in Table 2. In one group, containing nasopharyngeal specimens listed as 1 through 25, Spn strains were isolated and identified using both traditional and genomic methods. In the other group (i.e., nasopharyngeal specimens 26 through 50) Spn cultures were negative.

315 DNA was extracted from these nasopharyngeal samples and utilized as template in qPCR reactions targeting the species-specific lytA gene. Nasopharyngeal specimens 26 through 50 316 317 tested negative for Spn using lytA-PCR. As expected, lytA-PCR was positive for all 318 nasopharyngeal specimens 1 to 25 (Table 2). The specimens were processed microscopically 319 using fluorescently labeled antibodies, following the algorithm outlined in Figure 2A. Five distinct fields were examined within each preparation. The sensitivity of Spn-FLUO for detecting 320 321 Spn strains in human nasopharyngeal specimens was 96% (24/25), while specificity was 100% as no Spn was detected in *lytA*-negative, culture-negative specimens. A typical microscopy 322 finding from specimens containing abundant Spn (i.e., +++) is shown in Fig. 2C-D. The lowest 323 bacterial density detected by fluorescent antibody staining was 1.61x10⁴ GenEg/ml (Table 2 324 325 and Fig. 2B).

2-Oct-24

327 Detection and quantification of Streptococcus pneumoniae in mouse lung tissue during 328 **pneumonia.** We next conducted a pre-clinical evaluation of Spn-FLUO for the detection of pneumococci in lung specimens using a murine model of pneumococcal pneumonia. Mice were 329 infected with Spn strain TIGR4 and euthanized when moribund. Lungs were collected, 330 homogenized, and the Spn bacterial load was determined by serial dilution and plating (Table 331 3). Lungs from mice infected with an isogenic capsule-deficient mutant ($\Delta spxB\Delta/ctO$) that has a 332 defect for colonization^{43, 44} served as controls. As expected, all animals infected with TIGR4 333 exhibited a high lung colonization density of 1.18×10^7 (interguartile range: 2.37×10^6 - 1.12×10^8) 334 colony-forming units (CFU)/g, whereas those infected with the isogenic mutant displayed low 335 colonization levels (Fig. 3A). Spn was detected in all lung specimens from TIGR4-infected 336 animals at varying levels of positivity. In contrast, mutant-infected animals exhibited 337 significantly lower bacterial burdens, with $<1x10^3$ cfu/g or no detectable bacteria (Fig. 3B, 3C) 338 and Table 3). Specimens with the highest density and positive Spn-FLUO detection were 339 340 statistical different compared to those containing a lower burden of pneumococci (Fig. 3C). The highest positive reaction with Spn-FLUO was achieved in lungs from mice colonized with a 341 median of 1.41x10⁸ CFU/g, which was statistically significant compared to groups with lower 342 detection levels (Fig. 3B). Thus, Spn-FLUO demonstrated a strong correlation between 343 fluorescence detection of pneumococci and bacterial load in a murine model of pneumococcal 344 345 pneumonia, suggesting its potential as a rapid and sensitive diagnostic tool.

346

Detection of pneumococcal strains using Spn-FLUO in clinical specimens from patients with
 pneumococcal pneumonia. We subsequently evaluated the sensitivity of Spn-FLUO antibodies

2-Oct-24

in detecting pneumococcal strains within human specimens from patients with pneumococcal pneumonia. To assess this, we analyzed N=27 clinical specimens obtained from patients with microbiologically confirmed pneumococcal pneumonia, each yielding a pneumococcal isolate. Specimens comprised sputum and bronchioalveolar lavage fluid (Table 4). DNA was extracted from all 27 specimens, each of which yielded a positive *lytA*-based qPCR result, indicating varying bacterial loads expressed as genome equivalents per milliliter (GE/ml). Consistently, all specimens were also positive for *piaB* (data not shown).

356 Spn-FLUO identified the pneumococcal etiology in 25/27 specimens, resulting in percent positive agreement of 92.6%. Specimens with high pneumococcal detection per field using Spn-357 FLUO contained a median bacterial load of 1.13x10⁸ GE/ml by lytA-based qPCR (interguartile 358 range: 4.57x10⁷ - 4.85x10⁸) (Fig. 4A and Table 4). Specimens with low-moderate (i.e., scored +, 359 and ++) detection of Spn per field had a median bacteria load of 5.10×10^5 GE/ml (interquartile 360 range: 1.11×10^5 - 2.96x10⁶), while the specimen with the lowest GE/ml that yielded a positive 361 reaction with the Spn-FLUO antibodies contained 3.63x10³ GE/ml of pneumococcal DNA (Fig. 362 4A). 363

Representative images of Spn detected in sputum specimens are shown in Figure 4B-D. Fluorescence and bright-field microscopy revealed a heterogeneous mixture of epithelial cells, leukocytes, and bacteria resembling pneumococcal aggregates (Fig. 4B-D, arrows). While pneumococcal chains were also observed, these were less abundant than the bacterial aggregates. In a sputum specimen from a patient with pneumococcal pneumonia, additional bacteria were noted, although only pneumococci were stained by Spn-FLUO (Figure 4B-D,

2-Oct-24

arrowhead). In summary, Spn-FLUO detected Spn strains in 92.6% of clinical specimens from
 patients with pneumococcal pneumonia within 30 min.

372

373 Ultrastructural studies of Streptococcus pneumoniae in human sputum. Given the presence of abundant mucus and thick smears in some specimens, as well as the observation of large 374 375 pneumococcal aggregates in unprocessed sputum, we performed high-resolution 3D confocal 376 analysis of sputum specimens. Sputum was stained with Spn-FLUO, DAPI, and wheat germ 377 agglutinin (WGA which binds to N-acetyl-D-glucosamine (GlcNAc) and sialic acid (SA) residues. GlcNAc/SA was utilized since sialic acid is a biomarker for mucin content⁴⁵. A middle optical 378 section of the XY, XZ (bottom panel), and YZ (side panel) focal planes revealed a large structure 379 composed of aggregated pneumococci, isolated smaller aggregates, and pneumococcal chains 380 381 (Fig. 5A and Video S1). An optical zoom revealed abundant DNA located adjacent to 382 pneumococcal aggregates, suggesting the release from neighboring cells or cellular lysis (Fig. 5B). Orthogonal XZ and YZ sections demonstrated that the aggregates were embedded within 383 the sputum (Fig. 5B, bottom panel). Pneumococci in closed proximity to cell nuclei, either in the 384 process of capsule loss or already decapsulated (i.e., D-CPS), were observed in regions of the 385 sputum resembling internalized bacteria (Fig. 5C). 386

We performed three-dimensional reconstruction of the capsule channel (green) from confocal z-stacks (Fig. 5D) and categorized pneumococci into two groups: those within aggregates (Fig. 5E) and those forming chains or dispersed within the preparation (Fig. 5F). Representative pneumococcal aggregates are shown in Fig. 5G. The area of these pneumococcal aggregates was significantly different compared to all other pneumococci (Fig.

2-Oct-24

5H). The median area of pneumococcal aggregates was 1336 μ m² (interquartile range: 959 – 2108 μ m²) whereas the median area of pneumococcal chains and dispersed bacteria was 9.15 μ m² (interquartile range: 3.6 – 14.3 μ m²) (Fig. 5G).

Further 3D analysis of orthogonal XY and XZ focal planes demonstrated that the GlcNAc/SA signal did not colocalize with pneumococcal aggregates but instead surrounded encapsulated pneumococci (Fig. 51). Overall, the data revealed that pneumococcal aggregates embedded in sputum specimens are significantly larger than those in chain or dispersed forms, potentially providing a physical barrier shielding pneumococci from sputum components.

400

401 **Discussion**

In this study, we demonstrated the feasibility of fluorescent antibody-based microscopy 402 403 for the rapid diagnosis of pneumococcal pneumonia. The entire process, from sample collection to final diagnosis, was completed within 30 min. Prompt identification of the causative agent is 404 crucial in severe pneumonia, often influencing patient outcomes⁹. Spn-FLUO offers a valuable 405 alternative for rapid diagnosis, particularly in cases where mortality remains high despite low 406 antibiotic resistance rates, as observed with serotype 3 strains in Spain⁴⁶. The rapid 407 identification of the pneumococcus in clinical specimens allows for timely adjustment of 408 empirical therapy, which is particularly important in severe cases. Although this technology 409 requires a fluorescence microscope, the objective nature of the fluorescent signal from Spn 410 strains makes fluorescence antibody-based detection suitable for resource-limited regions, as 411 DNA extraction, reaction mixtures, and real-time systems are not necessary, and minimal 412 training is required. Furthermore, clinical trials recruiting patients with pneumococcal 413

2-Oct-24

pneumonia can benefit from a swift decision on whether potential individuals with signs and
symptoms of pneumococcal pneumonia can be included in the trial.

Despite significant advancements in technology for the detection of pathogens causing 416 pneumonia, pneumococcal pneumonia diagnosis remains challenging⁹. The culture of lower 417 respiratory tract specimens, while considered the gold standard, is often associated with delays 418 419 and low sensitivity. Multiplexed PCR panels have demonstrated improved sensitivity to detect pathogens not recovered by culture, but they require substantial resources, specialized 420 equipment, and highly trained personnel, with turnaround times of several hours^{9, 10, 47}. Antigen 421 detection assays, such as those targeting the pneumococcal capsule, offer the advantage of 422 rapid turnaround time. However, their specificity to a single pathogen represents a limitation. 423 Nonetheless, they can be a life-saving tool in critical situations. 424

425 To the best of our knowledge, no previous studies have investigated the ultrastructure of pneumococci in freshly expectorated human sputum from patients with pneumonia. The 426 current study filled this gap by characterizing the unique structures formed by pneumococci in 427 the sputum. These bacterial aggregates are large, with a median size of 1336 μ m², and have not 428 been observed invading the lungs of patients with pneumococcal pneumonia or in the lungs of 429 mice infected with Spn strains. This population of pneumococci, which likely resides 430 extracellularly on bronchi and bronchioles, may be formed to resist the innate and adaptive 431 immune response. These aggregated extracellular pneumococci represent an important novel 432 population that may be more resistant to antibiotics and antimicrobial peptides. 433

434 Our study has some limitations. Notably, Spn-FLUO exclusively recognizes encapsulated 435 pneumococci, limiting its utility for detecting non-encapsulated strains. While the majority of

2-Oct-24

isolates express capsule, this limitation could hinder the detection of other non-encapsulated 436 strains⁴⁸. Additionally, studies evaluating Spn-FLUO sensitivity in both mouse lung specimens 437 and human lung specimens from patients with pneumococcal pneumonia involved specimens 438 from where strains were isolated in culture, suggesting a high bacterial load, later confirmed by 439 qPCR assays. We did not assess the specificity of Spn-FLUO against a panel of Spn-negative 440 human sputum samples or healthy subjects. Instead, as a surrogate, we utilized human 441 nasopharyngeal specimens with a lytA-negative reaction and lung specimens from mice 442 infected with a strain with a colonization defect and low capsule production. In both cases, 443 specificity was 100%. 444

In summary, we have characterized a rapid method for detecting the pneumococcus in clinical specimens from patients with pneumonia. Using the fluorescent antibodies developed in this study, we have provided novel ultrastructural information regarding a previously uncharacterized population of pneumococcal aggregates. This study serves a dual purpose. First, antibody-based detection of pneumococci can be further developed to guide empirical therapy while awaiting culture results. Second, it fosters novel research into pneumococcal aggregates, which may serve as reservoirs for the pneumococcus.

452

453 List of abbreviations

454 *Streptococcus pneumoniae*: Spn

455 Fluorescent antibodies against the pneumococcal capsule: Spn-FLUO

456 Quantitative polymerase chain reaction: qPCR

457 Limit of Detection: LOD

458 Genome equivalents/milliliter: GenEq/ml

- 459 Square micrometer: μm²
- 460 Minutes: min
- 461 Community-acquired pneumonia : CAP
- 462 Carbon dioxide: CO₂
- 463 Oxygen: O₂
- 464 Hours: h
- 465 Multiplex polymerase chain reaction: (m)PCR
- 466 Colony Forming Units: CFU
- 467 Colony forming units/gram: CFU/g
- 468 Wheat Germ Agglutinin: WGA
- 469 N-acetyl-D-glucosamine : GlcNAc
- 470 Sialic acid: SA
- 471 Blood agar plates: BAP
- 472 Todd Hewitt broth containing yeast extract: THY
- 473 Streptomycin: Str
- 474 Trimethoprim: Tmp
- 475 Tetracycline: Tet
- 476 Erythromycin: Ery
- 477 Microgram/milliliter: μg/ml
- 478 Phosphate Buffered Saline: PBS
- 479 Minimum Essential Medium: MEM
- 480 Fetal Bovine Serum: FBS
- 481 Paraformaldehyde: PFA
- 482 Bovine Serum Albumin: BSA
- 483 Micromole: μM
- 484 Institutional Animal Care and Use Committee: IACUC
- 485 National Science Foundation Animal Welfare Act: AWA

2-Oct-24

- 486 Institutional Review Board: IRB
- 487 University of Mississippi Medical Center: UMMC
- 488 World Health Organization: WHO
- 489 Nasopharyngeal: NP
- 490 Microliter: μl
- 491 Nanogram/microliter: ng/ μl
- 492 Megabase: Mb
- 493 Seconds: s

494

495 **Declarations**

496 **Ethics approval**

The research project "Mechanistic Studies of Broadly Reactive Antibodies for the 497 498 Treatment, Diagnosis, and Prevention of Pneumococcal Infection" has been reviewed by the Institutional Review Board (IRB) of the University of Mississippi Medical Center (Federalwide 499 Assurance FWA#00003630) and has been determined to be exempt from formal review. The 500 IRB concluded that the project meets the criteria for exemption as outlined in the U.S. 501 Department of Health and Human Services Regulations for the Protection of Human Subjects, 502 45 CFR 46.102(I) because this project does not research involving human subjects. As such, no 503 additional ethical review was required. 504

All experiments involving animals were performed with prior approval of and in accordance with protocol 1584 which was reviewed and approved by the UMMC Animal Care Committee. UMMC laboratory animal facilities have been fully accredited by the American Association for Accreditation of Laboratory Animal Care. Procedures were performed according

2-Oct-24

- 509 to the institutional policies, Animal Welfare Act, NIH guidelines, and American Veterinary
- 510 Medical Association guidelines on euthanasia.

511

- 512 **Consent to participate**
- 513 N/A
- 514
- 515 **Consent for publication**
- 516 N/A

517

518 Availability of data and materials

All data generated or analyzed during this study are included in this published article (and its supplementary information files) and are available from the corresponding author on reasonable request. The materials such as software, protocols or reagents were specified in the Material and Methods section.

523

- 524 **Competing interests**
- 525 The authors declare that they have no competing interests.

2-Oct-24

527 Funding

528	This study was supported in part by a grant from the National Institutes of Health (NIH;
529	5R21AI144571-03, R01AI173084-03 and 1R01AI175461-01A1) and by a grant from NIGMS
530	through the Molecular Center of Health and Disease (1P20GM144041-01A1 7651). Studies of
531	confocal microscopy, and histology, were supported by grants from the National Institute of
532	General Medical Sciences (NIGMS) of the National Institutes of Health under Award Numbers
533	P20GM121334 and P20GM104357. The content is solely the responsibility of the authors and
534	does not necessarily represent the official view of the NIH.
535	
536	Authors' contributions
537	A.G.J.V Formal analysis, Investigation, Supervision, Methodology, Project administration,
537 538	A.G.J.V Formal analysis, Investigation, Supervision, Methodology, Project administration, Writing - review & editing.
537 538 539	 A.G.J.V Formal analysis, Investigation, Supervision, Methodology, Project administration, Writing - review & editing. M.F Formal analysis, Investigation.
537 538 539 540	 A.G.J.V Formal analysis, Investigation, Supervision, Methodology, Project administration, Writing - review & editing. M.F Formal analysis, Investigation. M.C Investigation.

- 542 P.S. Investigation.
- 543 P.V.- Investigation.
- 544 C.F. L.- Investigation, Methodology, Writing- review & editing.
- 545 C.G. Investigation, Methodology, Writing review & editing.

2-Oct-24

- 546 W.D. Investigation.
- 547 J.E.V. -Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation,
- 548 Writing original draft, Writing review & editing.
- 549 All authors read and approved the final manuscript.
- 550 Acknowledgements. We thank Dr. Babek Alibayov from the University of Mississippi Medical
- 551 Center (UMMC) for their assistance with labeling aliquots of Spn-FLUO, and Dr. Kenichi
- 552 Takeshita, and Dr. Antonino Baez, also from UMMC, for their feedback on the manuscript. The
- authors also acknowledge the assistance of Dr. Fuminori Sakai from Emory University Rollins
- 554 School of Public Health, currently at Pfizer Japan, for performing some qPCR assays.

555

556 References

- 558 1. Wahl, B. et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease 559 in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. 560 Lancet Glob Health 6, e744-e757 (2018). 561 2. Weiser, J.N., Ferreira, D.M. & Paton, J.C. Streptococcus pneumoniae: transmission, colonization 562 563 and invasion. Nat Rev Microbiol 16, 355-367 (2018). 564 565 3. Musher, D.M. & Thorner, A.R. Community-acquired pneumonia. *N Engl J Med* **371**, 1619-1628 566 (2014). 567 568 4. Ganaie, F. et al. A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large 569 cps Fragment from an Oral Streptococcus. mBio 11 (2020). 570 5. 571 Brissac, T. et al. Capsule Promotes Intracellular Survival and Vascular Endothelial Cell 572 Translocation during Invasive Pneumococcal Disease. mBio 12, e0251621 (2021).
- 573

574 575 576	6.	Hyams, C., Camberlein, E., Cohen, J.M., Bax, K. & Brown, J.S. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. <i>Infect Immun</i> 78 , 704-715 (2010).	
577 578 579	7.	Kim, J.O. <i>et al.</i> Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. <i>Infect Immun</i> 67 , 2327-2333 (1999).	
580 581 582 583	8.	Miller, J.M. <i>et al.</i> A Guide to Utilization of the Microbiology Laboratory for Diagnosis of nfectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. <i>Clin Infect Dis</i> 67 , e1-e94 (2018).	
584 585 586	9.	Pletz, M.W. <i>et al.</i> Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group. <i>Respir Res</i> 23 , 239 (2022).	
587 588 589 590	10.	Walker, A.M., Timbrook, T.T., Hommel, B. & Prinzi, A.M. Breaking Boundaries in Pneumonia Diagnostics: Transitioning from Tradition to Molecular Frontiers with Multiplex PCR. <i>Diagnostics</i> (Basel) 14 (2024).	
591 592 593 594	11.	Marimuthu, S., Damiano, R.B. & Wolf, L.A. Performance Characteristics of a Real-Time PCR Assay for Direct Detection of Streptococcus pneumoniae in Clinical Specimens. <i>J Mol Diagn</i> 26 , 552-562 (2024).	
595 596 597	12.	Carvalho Mda, G. <i>et al.</i> Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. <i>J Clin Microbiol</i> 45 , 2460-2466 (2007).	
598 599 600	13.	Wyllie, A.L. <i>et al.</i> Streptococcus pneumoniae in saliva of Dutch primary school children. <i>PLoS</i> <i>One</i> 9 , e102045 (2014).	
601 602 603	14.	Tavares, D.A. <i>et al.</i> Identification of Streptococcus pneumoniae by a real-time PCR assay targeting SP2020. <i>Sci Rep</i> 9 , 3285 (2019).	
604 605 606 607	15.	Shkodenko, L.A., Mohamed, A.A., Ateiah, M., Rubel, M.S. & Koshel, E.I. A DAMP-Based Assay for Rapid and Affordable Diagnosis of Bacterial Meningitis Agents: Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae. <i>Int J Mol Sci</i> 25 (2024).	
608 609 610 611	16.	Gotts, J.E. <i>et al.</i> Clinically relevant model of pneumococcal pneumonia, ARDS, and nonpulmonary organ dysfunction in mice. <i>Am J Physiol Lung Cell Mol Physiol</i> 317 , L717-L736 (2019).	
612 613 614	17.	Lee, J.S., Giesler, D.L., Gellad, W.F. & Fine, M.J. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review. <i>JAMA</i> 315 , 593-602 (2016).	

615 616 617 618	18.	Wu, X. <i>et al.</i> Effect of pneumococcal conjugate vaccine availability on Streptococcus pneumoniae infections and genetic recombination in Zhejiang, China from 2009 to 2019. <i>Emerg Microbes Infect</i> 11 , 606-615 (2022).
619 620 621	19.	Viteri-Davila, C. <i>et al.</i> The Crisis of Macrolide Resistance in Pneumococci in Latin America. <i>Am J</i> <i>Trop Med Hyg</i> (2024).
622 623 624	20.	Tettelin, H. <i>et al.</i> Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. <i>Science</i> 293 , 498-506 (2001).
625 626 627	21.	Wu, X. <i>et al.</i> Interaction between Streptococcus pneumoniae and Staphylococcus aureus Generates (.)OH Radicals That Rapidly Kill Staphylococcus aureus Strains. <i>J Bacteriol</i> 201 (2019).
628 629 630	22.	McDevitt, E. <i>et al.</i> Hydrogen Peroxide Production by Streptococcus pneumoniae Results in Alpha-hemolysis by Oxidation of Oxy-hemoglobin to Met-hemoglobin. <i>mSphere</i> 5 (2020).
631 632 633 634	23.	Lanie, J.A. <i>et al.</i> Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. <i>J Bacteriol</i> 189 , 38-51 (2007).
635 636 637	24.	Junges, R., Maienschein-Cline, M., Morrison, D.A. & Petersen, F.C. Complete Genome Sequence of Streptococcus pneumoniae Serotype 19F Strain EF3030. <i>Microbiol Resour Announc</i> 8 (2019).
638 639 640	25.	Wu, X. <i>et al.</i> Competitive Dominance within Biofilm Consortia Regulates the Relative Distribution of Pneumococcal Nasopharyngeal Density. <i>Appl Environ Microbiol</i> 83 (2017).
641 642 643 644	26.	Wu, X. <i>et al.</i> Ultrastructural, metabolic and genetic characteristics of determinants facilitating the acquisition of macrolide resistance by Streptococcus pneumoniae. <i>Drug Resist Updat</i> 77 , 101138 (2024).
645 646 647 648	27.	Alibayov, B. <i>et al.</i> Oxidative Reactions Catalyzed by Hydrogen Peroxide Produced by Streptococcus pneumoniae and Other Streptococci Cause the Release and Degradation of Heme from Hemoglobin. <i>Infect Immun</i> 90 , e0047122 (2022).
649 650 651 652	28.	Sakai, F., Sonaty, G., Watson, D., Klugman, K.P. & Vidal, J.E. Development and characterization of a synthetic DNA, NUversa, to be used as a standard in quantitative polymerase chain reactions for molecular pneumococcal serotyping. <i>FEMS Microbiol Lett</i> 364 (2017).
653		

654 655 656	29.	Pholwat, S., Sakai, F., Turner, P., Vidal, J.E. & Houpt, E.R. Development of a TaqMan Array Card for Pneumococcal Serotyping on Isolates and Nasopharyngeal Samples. <i>J Clin Microbiol</i> 54 , 1842-1850 (2016).
657 658 659 660	30.	Chien, Y.W. <i>et al.</i> Density interactions among Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. <i>Pediatr</i> <i>Infect Dis J</i> 32 , 72-77 (2013).
661 662 663	31.	Grijalva, C.G. <i>et al.</i> Cohort profile: The study of respiratory pathogens in Andean children. <i>Int J</i> Epidemiol 43 , 1021-1030 (2014).
664 665 666 667	32.	Howard, L.M. <i>et al.</i> Association between nasopharyngeal colonization with multiple pneumococcal serotypes and total pneumococcal colonization density in young Peruvian children. <i>Int J Infect Dis</i> 134 , 248-255 (2023).
668 669 670	33.	Nelson, K.N. <i>et al.</i> Dynamics of Colonization of Streptococcus pneumoniae Strains in Healthy Peruvian Children. <i>Open Forum Infect Dis</i> 5 , ofy039 (2018).
671 672 673 674	34.	Satzke, C. <i>et al.</i> Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. <i>Vaccine</i> 32 , 165-179 (2013).
675 676 677 678	35.	O'Brien, K.L. <i>et al.</i> Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. <i>J Clin Microbiol</i> 39 , 1021-1024 (2001).
679 680 681	36.	Sakai, F., Talekar, S.J., Klugman, K.P. & Vidal, J.E. Expression of Virulence-Related Genes in the Nasopharynx of Healthy Children. <i>PloS one</i> 8 , e67147 (2013).
682 683 684	37.	Centers for Desease Control and Prevention & (CDC). Streptococcus pneumoniae carriage study protocol - nasopharyngeal (NP) swab processing.; 2010.
685 686 687	38.	Leber, A.L. <i>Clinical microbiology procedures handbook,</i> 4th edition. edn. ASM Press: Washington, DC, 2016.
688 689 690 691	39.	Scott, E.J., 2nd, Luke-Marshall, N.R., Campagnari, A.A. & Dyer, D.W. Draft Genome Sequence of Pediatric Otitis Media Isolate Streptococcus pneumoniae Strain EF3030, Which Forms In Vitro Biofilms That Closely Mimic In Vivo Biofilms. <i>Microbiol Resour Announc</i> 8 (2019).
692 693 694	40.	Vidal, J.E. <i>et al.</i> Prophylactic inhibition of colonization by Streptococcus pneumoniae with the secondary bile acid metabolite deoxycholic acid. <i>Infect Immun</i> , IAI0046321 (2021).

695 696 697	41.	Vidal, J.E. <i>et al.</i> Prophylactic Inhibition of Colonization by Streptococcus pneumoniae with the Secondary Bile Acid Metabolite Deoxycholic Acid. <i>Infect Immun</i> 89 , e0046321 (2021).
698 699 700 701	42.	Hanke, C.R. <i>et al.</i> Bacterial Density, Serotype Distribution and Antibiotic Resistance of Pneumococcal Strains from the Nasopharynx of Peruvian Children Before and After Pneumococcal Conjugate Vaccine 7. <i>Pediatr Infect Dis J</i> 35 , 432-439 (2016).
702 703 704 705	43.	Echlin, H., Frank, M., Rock, C. & Rosch, J.W. Role of the pyruvate metabolic network on carbohydrate metabolism and virulence in Streptococcus pneumoniae. <i>Mol Microbiol</i> 114 , 536-552 (2020).
706 707 708	44.	Alibayov, B. <i>et al.</i> Oxidation of hemoglobin in the lung parenchyma facilitates the differentiation of pneumococci into encapsulated bacteria. <i>bioRxiv</i> (2023).
709 710 711	45.	Esther, C.R., Jr. <i>et al.</i> Sialic acid-to-urea ratio as a measure of airway surface hydration. <i>Am J</i> Physiol Lung Cell Mol Physiol 312 , L398-L404 (2017).
712 713 714	46.	Calvo-Silveria, S. <i>et al.</i> Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study. <i>Lancet Reg Health Eur</i> 41 , 100913 (2024).
715 716 717	47.	Riccobono, E., Bussini, L., Giannella, M., Viale, P. & Rossolini, G.M. Rapid diagnostic tests in the management of pneumonia. <i>Expert Rev Mol Diagn</i> 22 , 49-60 (2022).
718 719 720	48.	Keller, L.E., Robinson, D.A. & McDaniel, L.S. Nonencapsulated Streptococcus pneumoniae: Emergence and Pathogenesis. <i>mBio</i> 7 , e01792 (2016).
721		
722 723 724 725 726 727 728 729 720		

2-0ct-24

731 Figure legends



732

Figure 1. In vitro and in vivo detection of pneumococci with fluorescently-labelled antibodies. 733 Strain TIGR4 (A) was mixed with anti S4-A488 (green) antibody and observed under a 734 735 epifluorescence microscope within five minutes. (B) Spn serotype 19F strain 4924 was cultured for four h in a 8-well slide and pneumococci attached to the substratum were stained with an 736 737 anti S19-A555 (red) antibody and the DNA was stained with DAPI. (C-D) Human pharyngeal cells grown to confluence were inoculated with (C) strain D39 or (D) a mixture of strain D39 and 738 739 strain TIGR4 and incubated for four hours. D39 was stained with S2-A555 (red) and TIGR4 was stained with S4-A488. In panel C, DNA was stained with TO-PRO-3, while in panel D, it was 740 stained with DAPI. (E-F) C57BL/6 mice (N=11) were intranasally inoculated with serotype 19F 741 strain EF3030. After 48 h, mice were euthanized, and the nasal bone was removed. 742 Nasopharyngeal tissue was collected, sectioned (~5 μ m), or homogenized. Nasopharyngeal 743 homogenate (E) or tissue sections (F) were stained with DAPI and with an anti S19-A555 744 antibody. Arrows point out Spn. In panels B-F, micrographs were obtained by confocal 745 746 microscopy, and the projection of z-stacks is shown. (G) Nasopharyngeal homogenates were

2-0ct-24

- 747 diluted and plated to obtain the bacterial density. The density in the plot was grouped
- 748 according to whether the samples yielded a positive reaction with Spn-FLUO or were not
- 749 detected (ND). Student t test, ***p*=0.01.



Figure 2. Detection of *S. pneumoniae* with Spn-FLUO in human specimens. (A) Detection algorithm for the identification of Spn in clinical specimens. Five fields were screened using the 60x objective, and a specimen was scored positive when ≥ 1 to <5 (+), ≥ 5 to <10 (++), or ≥ 10 (+++) pneumococci were observed in at least three fields. This algorithm was chosen to ensure the reliable detection of Spn while minimizing the risk of false positives. (B) The density of *S. pneumoniae* in nasopharyngeal specimens that yielded a positive reaction with Spn-FLUO was categorized depending on the semiquantitative algorithm. Data are presented as mean \pm SD.

2-Oct-24

Differences in bacterial density were determined using one-way ANOVA followed by Dunnett's
multiple comparisons test. ns=no significant difference. (C-D) Sputum specimen stained with
Spn-FLUO and observed under (C) bright field and (D) epifluorescence in the green channel.
Arrows point out Spn identified by Spn-FLUO.



Figure 3. Detection of S. pneumoniae with Spn-FLUO in mouse lung specimens. Balb/c mice 764 were intranasally inoculated with strain TIGR4 or isogenic mutant $\Delta spxB\Delta lctO$ and euthanized 765 766 when deemed moribund, or after 96 h post-infection. Lungs were collected and homogenized. (A) Lung homogenates were diluted and plated to obtain the bacterial density. (B) Aliquots of 767 lung homogenate were stained with Spn-FLUO and scored for the presence of pneumococci. 768 769 Micrographs were obtained with a fluorescence microscope in the green channel. The top panel shows a representative specimen scored "+" with arrows pointing out S. pneumoniae, while the 770 bottom panel shows a representative specimen that scored "+++". (C) The density in the 771

2-0ct-24

graphic was grouped according to the semiquantitative detection of *S. pneumoniae* with SpnFLUO. Statistical significance of differences in bacterial density were determined using
Student's t-test (A) or one-way ANOVA followed by Dunnett's multiple comparisons test (C).
*p=0.027, **p=.0088, ***p=0.0007.

776



Figure 4. Detection of *S. pneumoniae* with Spn-FLUO in human sputum. (A) Aliquots of sputum were DNA extracted and used as templates in qPCR reactions targeting the *lytA* gene. Other aliquots were stained with Spn-FLUO, and the presence of *S. pneumoniae* was scored. The

2-Oct-24

781	graphic shows the pneumococcal genome equivalent (GenEq)/ml in all samples, categorized as
782	low (scored +), medium (scored ++), or high (scored +++). Statistical significance of differences
783	in bacterial density was assessed using the Student's t-test. ns=no significant difference. (B-D)
784	Sputum specimens stained with Spn-FLUO and observed under (B) epifluorescence in the green
785	channel or (C) bright field. Panel (D) shows the merged epifluorescence and bright field
786	channels. Arrows point out S. pneumoniae identified by Spn-FLUO, while arrowheads signal
787	staphylococcus-like microcolonies, which were not stained by Spn-FLUO but were observed in
788	the bright field channels.



790

791

Figure 5. Ultrastructural analysis of *S. pneumoniae* in human sputum. Sputum specimens were stained with Spn-FLUO (green), wheat germ agglutinin (WGA) labeled with Alexa 555 (red), and DNA was stained with DAPI (blue). Preparations were analyzed by confocal microscopy. Panel (A) shows middle XY, XZ (bottom), and YZ (side) optical sections. The white inset indicates an optical zoom shown in panel (B), while the yellow inset indicates the region shown in panel (C). The bottom panels in (B and C) show orthogonal XZ and YZ sections. Decapsulated pneumococci (D-CPS) are indicated by the arrows. (D-F) A mask was created in the green channel (D) to

2-Oct-24

799 analyze the 3D structure of the pneumococcal (E) aggregate or (F) dispersed pneumococci. (G) 800 Representative 3D images of aggregated pneumococci across the sputum specimen, showcasing their size, shape, and spatial distribution within the sputum. (H) The area of those 801 802 aggregate pneumococci and that of dispersed bacteria was plotted. Student's t-test was performed to assess statistical significance, ****p<0.0001. (I) Orthogonal XY and YZ sections 803 804 were created using the green (Spn-FLUO) and the red channel (WGA). WGA binds acetyl 805 glucosamine and sialic acid residues (GlcNAc/SA). The top panel shows the masked green channel representing the area of the pneumococcal aggregate. The pneumococcal aggregate 806 was removed from the middle panel to reveal the hollow spaces occupied by bacteria 807 embedded in the sputum. The bottom panel shows the non-masked green channel and the red 808 channel. All analyses were performed using the Imaris software. 809

2-Oct-24

Mouse nasopharynx	Density (cfu/organ)	Spn-FLUO*	S19-A555*
MN-1	7.1x10 ³	ND	ND
MN-2	3.27x10 ⁵	+	+
MN-3	4.93x10 ⁵	+	+
MN-4	1.4×10^4	+	+
MN-5	1.47×10^{5}	+	+
MN-6	4.83x10 ⁵	+	+
MN-7	1.0×10^{3}	ND	ND
MN-8	4.5x10 ³	ND	ND
MN-9	7.2x10 ⁴	+	+
MN-10	3.07x10 ⁴	+	+
MN-11	2.09x10 ⁵	+	+

Table 1. Detection of pneumococci using Spn-FLUO in the upper respiratory tract of mice.

812 *ND=not detected.

+, up to five pneumococci per field in at least three fields of five observed using

the 60x objective.

2-Oct-24

Table 2. Detection of Spn in nasopharyngeal specimens from children with Spn-FLUO.

818

Nasopharyngeal specimen	qPCR (GenEq/ml) [#]	Spn-FLUO*
HN-1	5.73E+05	+++
HN-2	1.67E+06	+++
HN-3	1.61E+04	+
HN-4	2.60E+06	++
HN-5	1.46E+04	++
HN-6	4.47E+06	++
HN-7	1.20E+06	+++
HN-8	1.49E+05	++
HN-9	4.70E+05	++
HN-10	2.72E+05	+++
HN-11	1.75E+04	ND
HN-12	1.51E+04	++
HN-13	1.26E+06	+++
HN-14	5.83E+05	++
HN-15	1.08E+05	+++
HN-16	1.87E+04	++
HN-17	8.65E+05	++
HN-18	2.92E+06	+++
HN-19	3.81E+05	+
HN-20	1.67E+05	++
HN-21	4.18E+05	++
HN-22	1.08E+05	+
HN-23	1.12E+05	+
HN-24	7.64E+06	++
HN-25	8.88E+06	++
HN-26 to HN-50	Negative	Negative

819 *[#]lytA*-based qPCR assay. ND=not detected.

820

821

2-Oct-24

Mouse (strain)	Density (cfu/ml)	Spn-FLUO
ML-1 (TIGR4)	6.25E+07	+++
ML-2 (TIGR4)	2.39E+08	+++
ML-3 (TIGR4)	1.39E+04	+
ML-4 (TIGR4)	2.38E+06	++
ML-5 (TIGR4)	1.09E+08	+++
ML-6 (TIGR4)	4.23E+05	+
ML-7 ($\Delta spxB\Delta lctO$)	5.28E+03	ND
ML-8 ($\Delta spxB\Delta lctO$)	4.03E+02	ND
ML-9 (TIGR4)	2.35E+06	+
ML-10 (TIGR4)	3.60E+06	+
ML-11 (TIGR4)	7.40E+06	+
ML-12 ($\Delta spxB\Delta lctO$)	0.00E+00	ND
ML-13 ($\Delta spxB\Delta lctO$)	0.00E+00	ND
ML-14 (TIGR4)	1.21E+08	+++
ML-15 (TIGR4)	1.41E+08	+++
ML-16 (TIGR4)	1.62E+07	+++
ML-18 (TIGR4)	2.18E+07	+++
ML-19 (TIGR4)	3.64E+06	++

Table 3. Detection of pneumococci using Spn-FLUO in the lung of mice.

2-Oct-24

Table 4. Detection of Spn in culture-positive specimen from patients with pneumococcal pneumonia using Spn-FLUO.

Specimen	ID	Specimen	qPCR (GE/ml)*	Spn-FLUO
HL1	082W	Sputum	3.25x10 ⁶	+
HL2	U019	BAL ^{&} (endotracheal Tube)	5.45x10 ⁷	+++
HL3	U0134	Sputum	6.16x10 ⁵	+
HL4	U146	Sputum	5.10x10 ⁵	+
HL5	U265	Sputum	3.63x10 ³	+
HL6	U2275	BAL (endotracheal Tube)	ND	+++
HL7	U6831	BAL (endotracheal Tube)	7.29x10 ⁹	+
HL8	U077	Sputum	2.73x10 ⁵	+
HL9	U097	Sputum	1.84x10 ⁵	+
HL10	U260	Sputum	1.81x10 ⁶	+
HL11	U227.46	BAL (endotracheal Tube)	4.85x10 ⁸	+++
HL12	U080	Sputum	1.10x10 ⁷	+
HL13	U081	Sputum	1.31x10 ⁷	++++
HL14	U081-W	Sputum	7.54x10 ⁴	+
HL15	U220	Sputum	2.60x10 ⁵	+
HL16	U766	Sputum	6.36x10⁵	-
HL17	U156	Sputum	7.56x10⁵	+
HL18	U209	Sputum	2.67x10 ⁶	+
HL19	U210	Sputum	5.32x10 ⁴	-
HL20	U501	Sputum	3.95x10 ⁴	++
HL21	UC1	Sputum	5.06x10 ⁷	++
HL22	UC2	Throat swab	1.48.x10 ⁵	++
HL23	UC3	Throat swab	1.57x10 ⁴	+
HL24	UC4	Sputum	4.57x10 ⁷	++++
HL25	UC4	Endotracheal aspirate	1.13x10 ⁸	++++
HL26	UC5	BAL (endotracheal tube)	3.84x10 ⁸	+++
HL27	UE1	BAL (endotracheal tube)	8.19x10 ⁶	++

837 *Genome equivalent/ml; *Bronchoalveolar lavage,



















